CL2024001431A1 - Compuestos para tratar anemias asociadas a mds y otras afecciones - Google Patents
Compuestos para tratar anemias asociadas a mds y otras afeccionesInfo
- Publication number
- CL2024001431A1 CL2024001431A1 CL2024001431A CL2024001431A CL2024001431A1 CL 2024001431 A1 CL2024001431 A1 CL 2024001431A1 CL 2024001431 A CL2024001431 A CL 2024001431A CL 2024001431 A CL2024001431 A CL 2024001431A CL 2024001431 A1 CL2024001431 A1 CL 2024001431A1
- Authority
- CL
- Chile
- Prior art keywords
- mds
- conditions
- compounds
- anemia associated
- treat anemia
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 102000013009 Pyruvate Kinase Human genes 0.000 abstract 1
- 108020005115 Pyruvate Kinase Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280069P | 2021-11-16 | 2021-11-16 | |
| US202263357240P | 2022-06-30 | 2022-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001431A1 true CL2024001431A1 (es) | 2024-10-25 |
Family
ID=84887868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001431A CL2024001431A1 (es) | 2021-11-16 | 2024-05-14 | Compuestos para tratar anemias asociadas a mds y otras afecciones |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250108049A1 (https=) |
| EP (1) | EP4433057A1 (https=) |
| JP (1) | JP2024543345A (https=) |
| KR (1) | KR20240107326A (https=) |
| AU (1) | AU2022390088A1 (https=) |
| CA (1) | CA3236880A1 (https=) |
| CL (1) | CL2024001431A1 (https=) |
| IL (1) | IL312679A (https=) |
| MX (1) | MX2024005852A (https=) |
| TW (1) | TW202329935A (https=) |
| WO (1) | WO2023091414A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202509043A (zh) * | 2023-05-15 | 2025-03-01 | 美商阿吉歐斯製藥公司 | ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式 |
| WO2026076363A1 (en) | 2024-10-04 | 2026-04-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CA2989111C (en) | 2015-06-11 | 2023-10-03 | Agios Pharmaceuticals, Inc. | Methods of using pyruvate kinase activators |
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| KR102777452B1 (ko) | 2017-11-22 | 2025-03-10 | 아지오스 파마슈티컬스 아이엔씨. | N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의결정 형태 |
| WO2020237047A1 (en) | 2019-05-22 | 2020-11-26 | Agios Pharmaceuticals, Inc. | Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide |
-
2022
- 2022-11-15 IL IL312679A patent/IL312679A/en unknown
- 2022-11-15 EP EP22839539.8A patent/EP4433057A1/en active Pending
- 2022-11-15 JP JP2024526836A patent/JP2024543345A/ja active Pending
- 2022-11-15 MX MX2024005852A patent/MX2024005852A/es unknown
- 2022-11-15 CA CA3236880A patent/CA3236880A1/en active Pending
- 2022-11-15 AU AU2022390088A patent/AU2022390088A1/en active Pending
- 2022-11-15 TW TW111143555A patent/TW202329935A/zh unknown
- 2022-11-15 WO PCT/US2022/049969 patent/WO2023091414A1/en not_active Ceased
- 2022-11-15 US US18/711,090 patent/US20250108049A1/en active Pending
- 2022-11-15 KR KR1020247019391A patent/KR20240107326A/ko active Pending
-
2024
- 2024-05-14 CL CL2024001431A patent/CL2024001431A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3236880A1 (en) | 2023-05-25 |
| JP2024543345A (ja) | 2024-11-21 |
| EP4433057A1 (en) | 2024-09-25 |
| TW202329935A (zh) | 2023-08-01 |
| US20250108049A1 (en) | 2025-04-03 |
| AU2022390088A1 (en) | 2024-05-09 |
| MX2024005852A (es) | 2024-05-28 |
| WO2023091414A1 (en) | 2023-05-25 |
| KR20240107326A (ko) | 2024-07-09 |
| IL312679A (en) | 2024-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024001431A1 (es) | Compuestos para tratar anemias asociadas a mds y otras afecciones | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2022003000A1 (es) | Compuestos útiles para inhibir la quinasa ret | |
| BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
| CO2018011550A2 (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| BR112022012195A2 (pt) | Derivados de piperidina bicíclico substituídos úteis como ativadores de células t | |
| CL2022000835A1 (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| AR126251A1 (es) | Inhibidores de cdk2 | |
| MX2022000550A (es) | Imidazopirimidinas como inhibidores de eed y uso de estas. | |
| BR112023026538A2 (pt) | Pirazóis com pirimidinil substituído como inibidores de cdk2 | |
| PY1983118A (es) | Inhibidores de pde4 que contienen boro | |
| MX2024015648A (es) | Compuestos como inhibidores de axl | |
| MX2019008331A (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| PY1978496A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
| BR112019003710A2 (pt) | inibidor de pde7, composto, composição farmacêutica, uso de um inibidor de pde7 ou de um composto, e, método para tratar ou prevenir uma doença que é melhorada pela inibição de pde7. | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| CL2021000023A1 (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| CL2025001917A1 (es) | Compuestos lipídicos y composiciones de nanopartículas lipídicas | |
| CO2024010726A2 (es) | Compuestos heterocíclicos y métodos de uso | |
| BR112023004550A2 (pt) | Compostos tricíclicos substituídos | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| CR20220343A (es) | Agentes terapéuticos selectivos contra el cáncer inhibidores de cdk4/6 | |
| CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
| ECSP24007534A (es) | Inhibidores de transglutaminasas |